Endometriosis and menopause — the nuanced HRT picture
Women with endometriosis are often told they cannot take HRT at menopause — that it will reactivate their disease. The reality is considerably more nuanced. Rose covers when HRT is safe, which formulations to choose, the risk of postmenopausal endometriosis, and how to navigate this complex intersection.
Rose
"Women with endometriosis reaching perimenopause are some of the most underserved in menopause medicine — they have often been told they cannot have HRT, left to suffer debilitating menopause symptoms on top of a chronic pain condition. The evidence is that most women with endometriosis history can take HRT with appropriate formulation choice and monitoring. This page is the nuanced picture most women are never given."
Key takeaways
✓Women with endometriosis can generally take HRT at menopause — but the formulation matters significantly
✓Continuous combined HRT (not sequential/cyclical) is preferred — it avoids the estrogen-only phases that most stimulate residual lesions
✓Micronised progesterone is the preferred progestogen — it has the most anti-proliferative effect on endometriotic tissue
✓Postmenopausal endometriosis is more common than recognised — some lesions persist, particularly deep infiltrating or fibrotic disease
✓Endometriotic lesions produce their own estrogen via aromatase — which is why estrogen-only HRT carries higher reactivation risk
✓Specialist oversight combining endometriosis and menopause expertise is ideal for this complex intersection
✓Surgical menopause from endometriosis treatment carries the same HRT-essential considerations as any oophorectomy
The complexities — four things to understand
🔥
Endometriosis lesions can persist after menopause
Endometriosis is commonly described as an estrogen-dependent condition that resolves at menopause. This is partially true — the disease is driven by estrogen, and most lesions regress with the loss of cyclical estrogen stimulation. However, some lesions persist, particularly those that have become deeply infiltrating or fibrotic. Postmenopausal endometriosis — ongoing pain and lesion activity after menopause — is more common than previously recognised, particularly in women with severe disease history.
⚖️
HRT and endometriosis — a nuanced picture
For women with endometriosis entering menopause, the standard advice is often that HRT will reactivate the disease. The reality is more nuanced. The risk of reactivation exists primarily with estrogen-only HRT in women who still have residual endometriotic tissue. The risk is lower with combined HRT (estrogen plus progestogen) — particularly with continuous combined regimens that avoid the cyclical estrogen peaks of sequential HRT. Many women with a history of endometriosis can and should take HRT for menopause symptom management and long-term health protection.
🏥
Surgical menopause from endometriosis treatment
Bilateral oophorectomy is sometimes performed as part of severe endometriosis treatment — producing surgical menopause in potentially young women. The considerations for this group are the same as for any surgical menopause: HRT is essential health protection, bone and cardiovascular risk are elevated, and the decision should be made in full knowledge of the long-term hormonal consequences. See the surgical menopause guide for the full picture.
🧬
The aromatase problem — local estrogen production in lesions
Endometriotic lesions express aromatase — the enzyme that converts androgens to estrogen locally. This means endometriotic tissue can produce its own estrogen even in a postmenopausal hormonal environment, potentially sustaining lesion activity and pain. This is why aromatase inhibitors are sometimes used for postmenopausal endometriosis, and why estrogen-only HRT carries a greater reactivation risk than combined HRT in this population.
What actually helps — evidence graded
💊
HRT — combined continuous preferred over estrogen-only
Moderate evidenceWomen with a history of endometriosis who need HRT can generally take it — but the formulation choice matters. Continuous combined HRT (estrogen plus progestogen daily, without a cyclical break) avoids the estrogen-only phases of sequential HRT that most stimulate residual lesions. The progestogen component opposes estrogen's growth-stimulating effect on endometriotic tissue. Micronised progesterone is the preferred progestogen — it has the best safety profile and the most anti-proliferative effect on endometrial-type tissue.
Key points
• Continuous combined regimen avoids estrogen-only phases that stimulate lesions
• Micronised progesterone has direct anti-proliferative effects on endometriotic tissue
• Addresses the long-term bone, cardiovascular, and cognitive risks of estrogen deficiency
• Most women with endometriosis history tolerate HRT well — the risk of reactivation with combined continuous HRT is low
How to use this
Continuous combined transdermal estradiol plus micronised progesterone — discuss this specific formulation with your specialist. Sequential HRT (cyclical progestogen) has higher reactivation risk. Vaginal estrogen for local symptoms is safe. Monitor for recurrence of pain symptoms — if these develop, specialist review is needed.
🩺
Specialist oversight — endometriosis and menopause combined
Strong evidenceThe intersection of endometriosis and menopause is complex enough to warrant specialist input — ideally a gynaecologist with expertise in both endometriosis and menopause, or close collaboration between a menopause specialist and endometriosis specialist. Many decisions (HRT formulation, surgical considerations, pain management) require individual assessment of disease burden and lesion location.
Key points
• Individualised risk assessment for HRT reactivation based on disease severity and location
• Surveillance for postmenopausal endometriosis pain recurrence
• Assessment of residual lesion burden — imaging to guide HRT decision
• Management of pain that persists into menopause — which may have multiple causes
How to use this
Ask your GP for referral to a menopause specialist who has experience with endometriosis, or for a combined clinic if available. The British Society for Gynaecological Endoscopy (BSGE) accredited centres have the most specialist endometriosis expertise.
😴
Addressing the perimenopausal overlap symptoms
Strong evidenceWomen with endometriosis entering perimenopause face a particularly complex symptom picture — perimenopausal symptoms overlap with endometriosis symptoms (pelvic pain, fatigue, bowel and bladder symptoms). Distinguishing which symptoms are hormonal and which are disease-related requires careful assessment. HRT trial often clarifies the picture — symptoms that improve significantly with HRT were likely hormonal.
Key points
• HRT trial helps distinguish hormonal from disease-related symptoms
• Addressing sleep, anxiety, and mood with HRT improves overall pain experience — pain is amplified by sleep deprivation and anxiety
• Pelvic floor physiotherapy addresses the muscular pain component that often accompanies endometriosis
• Dietary anti-inflammatory approach reduces the systemic inflammation that drives both endometriosis and perimenopausal symptoms
How to use this
Start with a careful symptom diary distinguishing cyclical pain (more likely endometriosis) from constant symptoms (more likely other causes). Trial HRT and reassess at 3 months. Add pelvic floor physiotherapy for the musculoskeletal pain component. Anti-inflammatory diet as a supportive measure.
Rose on this
"You should not have to choose between managing your endometriosis and managing your menopause. With the right formulation and monitoring, most women with endometriosis can take HRT. The conversation with a specialist who understands both conditions is what makes this possible — and it is a conversation you deserve to have."
From Rose
"Years of living with endometriosis, and then menopause on top of it without hormonal support — that is an enormous burden. It does not have to be that way. The right HRT formulation, the right specialist, the right monitoring — these make combined endometriosis and menopause management possible and significantly better than leaving either untreated."
Related pages
Surgical menopause — oophorectomy for endometriosis ›
Types of HRT — continuous combined formulation explained ›
Progesterone — anti-proliferative effects on endometrial tissue ›
Pelvic floor — endometriosis and pelvic pain overlap ›
Written by
Rose
Navigating perimenopause · Researcher · Founded rosemyfriend.com
Research basis
PubMed · Cochrane reviews · NICE guidelines · British Menopause Society · The Menopause Society
Read methodology →
Last updated
March 2026
Rose provides evidence-graded educational information — not medical advice. Always discuss health decisions with a qualified healthcare provider. Full disclaimer · About Rose